<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00554775</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000573254</org_study_id>
    <secondary_id>CRUK-UCL-BRD-05-177</secondary_id>
    <secondary_id>BRD/05/177</secondary_id>
    <secondary_id>EUDRACT-2006-000113-38</secondary_id>
    <secondary_id>CRUK-TACTIC</secondary_id>
    <secondary_id>EU-20792</secondary_id>
    <secondary_id>ISRCTN31916843</secondary_id>
    <nct_id>NCT00554775</nct_id>
  </id_info>
  <brief_title>WBRT &amp; Erlotinib in Advanced NSCLC and Brain Metastases</brief_title>
  <acronym>TACTIC</acronym>
  <official_title>A Randomised Phase II Double Blind Placebo Controlled Trial of Whole Brain Radiotherapy (WBRT) and Tarceva (OSI-774, Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Multiple Brain Metastases [TACTIC]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. Erlotinib may stop&#xD;
      the growth of tumor cells by blocking some of the enzymes needed for cell growth. Erlotinib&#xD;
      may also make tumor cells more sensitive to radiation therapy. It is not yet known whether&#xD;
      giving whole-brain radiation therapy together with erlotinib is more effective than&#xD;
      whole-brain radiation therapy alone in treating patients with non-small cell lung cancer and&#xD;
      brain metastases.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying whole-brain radiation therapy and&#xD;
      erlotinib to see how well they work compared with whole-brain radiation therapy alone in&#xD;
      treating patients with advanced non-small cell lung cancer and brain metastases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the effect of whole-brain radiotherapy (WBRT) and erlotinib hydrochloride vs&#xD;
           WBRT alone on neurological progression-free survival at 2 months in patients with&#xD;
           advanced non-small cell lung cancer and multiple brain metastases.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the toxicity of these regimens.&#xD;
&#xD;
        -  Compare the response rate in these patients.&#xD;
&#xD;
        -  Compare quality of life of these patients.&#xD;
&#xD;
        -  Compare change in performance status in these patients.&#xD;
&#xD;
        -  Compare steroid dosing in these patients.&#xD;
&#xD;
        -  Compare sites of progression (cranial or extracranial) in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified by presence of extracranial&#xD;
      metastases (yes vs no), RTOG recursive partitioning analysis (RPA) score (I vs II) and&#xD;
      treatment center. Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients undergo whole-brain radiotherapy (WBRT) once daily for 5 days. Patients&#xD;
           also receive oral erlotinib hydrochloride once daily for up to 24 months.&#xD;
&#xD;
        -  Arm II: Patients undergo WBRT as in arm I. Patients also receive oral placebo once daily&#xD;
           for up to 24 months.&#xD;
&#xD;
      Quality of life is assessed at baseline, monthly for 12 months, and then at 18 and 24 months.&#xD;
&#xD;
      After completion of study therapy, patients are followed every 1-2 months.&#xD;
&#xD;
      Peer Reviewed and Funded or Endorsed by Cancer Research UK.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    IDMC made a recommendation to stop the trial as the target for continuing to the 2nd phase was&#xD;
    not met.&#xD;
  </why_stopped>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neurological progression-free survival at 2 months</measure>
    <time_frame>at 2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>during and for 28 days following Tarceva/placebo treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>from date of randomisation to radiological progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>completed monthly for the first 12 months and at 18 and 24 months from randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in performance status</measure>
    <time_frame>from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steroid dosing</measure>
    <time_frame>from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sites of progression (cranial or extracranial)</measure>
    <time_frame>from baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <arm_group>
    <arm_group_label>erlotinib hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>WBRT plus Tarceva (OSI-774, erlotinib) PO 100 mg daily during WBRT, increasing to 150mg daily after WBRT for up to 24 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>WBRT plus matched placebo for the same schedule and duration as erlotinib hydrochloride arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib hydrochloride</intervention_name>
    <description>PO 100 mg daily during WBRT, increasing to 150mg daily after WBRT for up to 24 months</description>
    <arm_group_label>erlotinib hydrochloride</arm_group_label>
    <other_name>tarceva</other_name>
    <other_name>OSI-774</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>WBRT plus matched placebo for the same schedule and duration as erlotinib hydrochloride</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed advanced non-small cell lung cancer (NSCLC)&#xD;
             meeting 1 of the following criteria:&#xD;
&#xD;
               -  Newly diagnosed multiple brain metastases not suitable for first-line&#xD;
                  chemotherapy&#xD;
&#xD;
               -  Relapsed NSCLC with newly diagnosed multiple brain metastases&#xD;
&#xD;
               -  Relapsed after second-line chemotherapy with newly diagnosed multiple brain&#xD;
                  metastases NOTE: *Biopsy of brain metastases is not required&#xD;
&#xD;
          -  Diagnosis of brain metastases must be confirmed by contrast CT scan or MRI within the&#xD;
             past 4 weeks&#xD;
&#xD;
               -  Symptoms attributable to brain metastases&#xD;
&#xD;
               -  Patients who have undergone craniotomy with incomplete resection are eligible&#xD;
&#xD;
          -  Clinician certain that whole-brain radiotherapy (WBRT) will be beneficial&#xD;
&#xD;
          -  No evidence of solitary brain metastasis on MRI that can be treated with surgical&#xD;
             resection, radiosurgery, or stereotactic radiotherapy&#xD;
&#xD;
          -  No more than 3 sites (organ systems) of extracranial metastases&#xD;
&#xD;
               -  No liver metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky performance status 70-100%&#xD;
&#xD;
          -  RTOG recursive partitioning analysis (RPA) class I or II&#xD;
&#xD;
          -  Serum bilirubin &lt; 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT &lt; 2 times ULN (&lt; 5 times ULN if liver metastases are present)&#xD;
&#xD;
          -  Creatinine &lt; 5 times ULN&#xD;
&#xD;
          -  Able to take oral medication&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Caretaker able and willing to participate in the study&#xD;
&#xD;
          -  Patient and caretaker have access to a telephone and willing to respond to telephone&#xD;
             interview&#xD;
&#xD;
          -  No other prior or concurrent malignant disease likely to interfere with study&#xD;
             treatment or comparisons&#xD;
&#xD;
          -  No evidence of other significant laboratory finding or concurrent uncontrolled medical&#xD;
             illness, that in the opinion of the investigator, would interfere with study treatment&#xD;
             or results comparison or render the patient at high risk for treatment complications&#xD;
             including, but not limited to, any of the following:&#xD;
&#xD;
               -  Severe uncontrolled infection&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  Myocardial infarction within the past month&#xD;
&#xD;
               -  Uncontrolled inflammatory bowel disease (e.g., Crohn's disease or ulcerative&#xD;
                  colitis)&#xD;
&#xD;
               -  Acute renal failure&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 28 days since prior chemotherapy (for relapsed patients originally treated&#xD;
             with chemotherapy)&#xD;
&#xD;
          -  No prior cranial radiotherapy&#xD;
&#xD;
          -  No prior anti-cancer EGFR therapy (e.g., erlotinib, gefitinib, or cetuximab)&#xD;
&#xD;
          -  No prior treatment for brain metastases (e.g., radiosurgery, radiotherapy, or&#xD;
             chemotherapy)&#xD;
&#xD;
               -  Prior radiotherapy to the primary tumor and/or systemic treatment to metastatic&#xD;
                  sites of disease allowed&#xD;
&#xD;
          -  No concurrent cyclooxygenase-2 (COX-2) inhibitors&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Siow M. Lee, MD, PhD, FRCP</last_name>
    <role>Study Chair</role>
    <affiliation>University College London Hospitals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charing Cross Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College of London Hospitals</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>WIT 3AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salisbury District Hospital</name>
      <address>
        <city>Salisbury</city>
        <state>England</state>
        <zip>SP2 8BJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <state>England</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glan Clwyd Hospital</name>
      <address>
        <city>Rhyl, Denbighshire</city>
        <state>Wales</state>
        <zip>LL18 5UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South West Wales Cancer Institute</name>
      <address>
        <city>Swansea</city>
        <state>Wales</state>
        <zip>SA2 8QA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <study_first_submitted>November 6, 2007</study_first_submitted>
  <study_first_submitted_qc>November 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2007</study_first_posted>
  <last_update_submitted>December 9, 2011</last_update_submitted>
  <last_update_submitted_qc>December 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tumors metastatic to brain</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

